How does lurbinectedin work with chemo in small cell lung cancer?
Lurbinectedin, sold as Zepzelca, targets the G2/M phase of the cell cycle and traps DNA in transcription complexes, killing rapidly dividing cancer cells. Combined with intravenous irinotecan (a topoisomerase inhibitor chemo), it shows antitumor activity in relapsed small cell lung cancer (SCLC). In phase Ib/II trials, the combo achieved a 52% overall response rate (ORR), with 6% complete responses and median duration of response of 5.4 months.[1][2]
What do trial results show for response and survival?
In the 51-patient expansion cohort of a phase I/II study, patients with sensitive relapsed SCLC had a 67% ORR, median progression-free survival (PFS) of 5.8 months, and median overall survival (OS) of 10.9 months. For resistant relapsed cases, ORR was 35%, PFS 3.5 months, and OS 6.2 months. These beat single-agent irinotecan benchmarks (ORR ~15-20%, PFS ~3 months).[1][3]
Why might this combo outperform chemo alone?
Lurbinectedin sensitizes SCLC cells to chemo by disrupting DNA repair and transcription, addressing resistance from prior platinum-based therapy. It fills a gap for second-line treatment post-platinum failure, where options were limited. FDA approved lurbinectedin monotherapy in 2020 based on similar rationale, but combo data suggest additive effects without excessive overlap in toxicity profiles.[2][4]
What are the main side effects and risks?
Common adverse events (grade 3/4) include neutropenia (51%), anemia (22%), thrombocytopenia (16%), and fatigue (12%). Febrile neutropenia hit 6%, with two treatment-related deaths from sepsis. Dose adjustments managed most myelosuppression, but monitoring is key for heavily pretreated patients.[1]
Is this approved, and what's next for other cancers?
The irinotecan combo lacks full FDA approval as of 2023; trials support its use in relapsed SCLC. Ongoing studies test lurbinectedin with other chemos like doxorubicin or paclitaxel in SCLC, pleural mesothelioma, and gynecologic cancers. No patent data specific to combos found on DrugPatentWatch.com.[2][5]
How does it stack up against other SCLC options?
Compared to topotecan (standard second-line chemo: ORR 15-24%, PFS 3.3 months), the lurbinectedin-irinotecan duo offers higher ORR and PFS. It rivals immunotherapy-chemo first-line regimens but targets relapsed disease. Trilaciclib pretreatment further boosts tolerability by protecting bone marrow.[3][6]
Sources:
[1] J Thorac Oncol. 2021;16(12):1967-1977
[2] FDA Approval Summary
[3] Same trial data
[4] N Engl J Med. 2020 monotherapy basis
[5] ClinicalTrials.gov ongoing trials
[6] Topotecan benchmarks